Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy - PubMed
4 hours ago
- #GPRC5D
- #immunotherapy
- #multiple myeloma
- GPRC5D is a promising target for immunotherapy in multiple myeloma (MM).
- Monoallelic loss of GPRC5D reduces surface antigen expression and confers resistance to GPRC5D-targeted therapies.
- Complete loss of GPRC5D alters transcriptional and phosphoproteomic states, creating a pro-proliferative environment.
- GPRC5D deficiency increases MM cell proliferation, providing a competitive advantage, especially under anti-GPRC5D immunotherapy.
- The study highlights potential challenges of GPRC5D-targeted treatments due to selection of aggressive, resistant myeloma phenotypes.